Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 in Heterozygous Familial Hypercholesterolemia (HeFH)
NCT07465263Phase 3Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 3 trial of SYH2053 in heterozygous familial hypercholesterolemia (HeFH), sponsored by CSPC Zhongnuo Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
SYH2053
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT07465263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465263.